NOVO — Maj 2025
-
Novo: FDA accepterer ansøgning om godkendelse af oral Wegovy https://proinvestor.com/investornyt/1312280/novo-fda-accepterer-ansogning-om-godkendelse-af-oral-wegovy
-
Novo brugte 50 Mio $ på tv reklame i USA i april. https://www.fiercepharma.com/marketing/abbvies-skyrizi-retakes-top-tv-ad-spending-spot-first-time-all-year Ned fra 62 mio i marts.
-
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
-
Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 – covering burden, and the value of treatment and prevention
Analysis of the landmark SELECT trial to uncover new insights into the early cardiovascular benefits of semaglutide
Real-world studies reinforce value of semaglutide in obesity -
Bagsværd, Denmark, 6 May 2025 – Novo Nordisk today announced that new data spanning the company’s industry-leading portfolio across metabolic and cardiovascular health will be presented at the upcoming 32nd European Congress on Obesity (ECO), 11–14 May 2025.
-
The data will further extend the wide-ranging evidence base for semaglutide through real-world evidence studies and additional analysis of the landmark cardiovascular outcomes trial, SELECT, as well as part 1 of the phase 3 ESSENCE trial in metabolic dysfunction-associated steatohepatitis (MASH). Data will also be presented on the wider societal impacts of treating and preventing obesity, alongside analysis of the burden of obesity in adolescents.
-
-
Berlinske om NOVO kræver abonnement https://www.berlingske.dk/virksomheder/her-er-novo-nordisks-nye-kampplads-vaegttabsbehandlinger-der-indtil
-
Novos kursmål løftes 15 pct. af Zacks https://proinvestor.com/investornyt/1313441/novos-kursmal-loftes-15-pct-af-zacks
-
Novo Nordisk: Lidt større nedjustering end ventet https://proinvestor.com/boards/126256
-
Novos nedjustering og toldfrygt kan tynge aktien spår Sydbank https://proinvestor.com/investornyt/1313471/novos-nedjustering-og-toldfrygt-kan-tynge-aktien-spar-sydbank
-
Novo Nordisk henter prioritetsstatus for Semaglutid i fedtlever i USA
Den nye status kan forkorte behandlingstiden for ansøgning til det amerikanske marked https://medwatch.dk/article18158335.ece (Medwatch) -
Novo Nordisk faldt tirsdag 3,9 pct. til 441,05 kr., og står til yderligere drop i størrelsesordenen 3 pct. onsdag ifølge indikationer fra Tradegate-børsen. Marketwire
-
Fra MW "Novo Nordisk har i februar i år indsendt ansøgning om markedsføringsgodkendelse af Semaglutid til behandling af fedtlever - eller MASH - i både EU og USA, og selskabet har i den forbindelse også fået såkaldt priority review-status i USA.
Det betyder, at de amerikanske sundhedsmyndigheder, Food and Drug Administration (FDA), forkorter behandlingstiden for ansøgningen."
-
Er der CC i dag?
-
Yes 1300
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind